After 70 days of single ICV administration of ASO1 was found to reduce SNCA mRNA by approximately 50%, prolonged the duration of action, and prevent pathogenic α-Syn aggregate deposition in an in vivo PFF model of PD. The gene discussed is SNCA; the disease is Parkinson disease.